Cidara Theraptcs SEC Filings

Cidara Therapeutics (CDTX) disclosed details about a clinical evaluation of CD388, specifying a 450-milligram dose versus placebo and a clearly defined primary endpoint based on laboratory-confirmed influenza, measured fever (≥ 37.2°C/99°F) and combinations of respiratory and systemic symptoms. The filing reiterates standard forward-looking statement language and points investors to the company's Quarterly Report for the period ended June 30, 2025 for additional risk factors.

The report emphasizes that outcomes and cash usage may differ from expectations and that the company does not intend to update forward-looking statements except as required by law. The filing is dated September 24, 2025 and is signed by Jeffrey Stein, Ph.D.

Cidara Therapeutics insider sale to cover RSU taxes Nicole Davarpanah, the company's Chief Medical Officer, sold 474 shares of Cidara Therapeutics common stock on 09/11/2025 to satisfy tax withholding obligations tied to vested restricted stock units. The weighted-average sale price reported is $62.8627, with transaction prices ranging from $62.86 to $63.50. After the reported sale, the reporting person beneficially owns 31,418 shares; this total includes 200 shares purchased through the company Employee Stock Purchase Plan on May 20, 2025. The Form 4 was executed by an attorney-in-fact on 09/15/2025.

Venrock group reports a 3.2% passive stake in Cidara Therapeutics (CDTX) held collectively as of June 30, 2025. The filing lists 639,088 shares beneficially owned across Venrock entities: 134,554 shares held by Venrock Healthcare Capital Partners III, L.P.; 13,456 by VHCP Co-Investment Holdings III, LLC; and 491,078 by Venrock Healthcare Capital Partners EG, L.P. All reporting entities are Delaware-organized and report shared voting and dispositive power over the 639,088 shares and no sole voting or dispositive power. The percentage is calculated using 20,163,696 shares outstanding per the issuer prospectus supplement dated June 24, 2025. Signatures and powers of attorney are included by reference.

Cidara Therapeutics, Inc. (CDTX) received a Schedule 13G/A reporting that Point72-affiliated entities and Steven A. Cohen beneficially own 1,527,930 shares of common stock, representing 7.6% of the outstanding class as of June 30, 2025. The filing states those shares are held for investment by Point72 Associates and that Point72 Asset Management and Point72 Capital Advisors maintain shared voting and dispositive power over the shares; none of the reporting persons claim sole voting or dispositive power. The reporting address is 72 Cummings Point Road, Stamford, CT.

Canaan XII L.P. and Canaan Partners XII LLC filed Amendment No. 1 to Schedule 13G reporting that, as of June 30, 2025, neither reporting person beneficially owns any shares of Cidara Therapeutics, Inc. common stock (CUSIP 171757206). The filing lists each filer’s jurisdiction of organization and principal business address and states the holders have 0 sole or shared voting and dispositive power, representing 0.0% of the class.

Cidara Therapeutics' Schedule 13G/A discloses that Vivo Opportunity Fund Holdings, L.P. (and its general partner Vivo Opportunity, LLC) beneficially owns 1,175,796 shares of Cidara common stock, representing 4.6% of the outstanding class. Vivo Opportunity Cayman Fund, L.P. (and its general partner Vivo Opportunity Cayman, LLC) beneficially owns 135,629 shares, representing 0.5% of the class. Each reporting person reports sole voting and sole dispositive power over the shares they hold of record through the funds. The filing states the holdings were not acquired to change or influence control of the issuer and ties beneficial ownership to the funds and their general partners as disclosed in the issuer's public filings.

Adage Capital Management and two principals report a passive 4.97% stake in Cidara Therapeutics (CDTX), holding 1,100,000 shares in shared voting and dispositive power. The filings identify Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as the reporting persons and state the position is held in the ordinary course of business and not to influence control. The percentage is calculated on a pro forma share count of 22,117,550 shares, which combines 12,969,823 outstanding shares as of May 5, 2025 and 9,147,727 shares issued under a June 25, 2025 prospectus after full exercise of the over-allotment.

The report shows 0 sole voting/dispositive power and 1,100,000 shares of shared voting/dispositive power, placing the holding under the 5% reporting threshold for greater-than-5% ownership.

RA Capital Management, its principals Peter Kolchinsky and Rajeev Shah, and RA Capital Healthcare Fund report beneficial ownership of 3,365,523 shares of Cidara Therapeutics common stock, representing 13.3% of 25,358,051 shares outstanding. The Fund also holds Series A preferred stock convertible into up to 6,296,920 common shares and pre-funded warrants exercisable for up to 1,286,786 common shares, but conversion and exercise are limited by contractual Beneficial Ownership Blockers that prevent the Fund from owning more than 9.99% of the common stock and currently prohibit conversion or exercise.

RA Capital is the investment adviser with sole power to vote and dispose of the Fund’s reported securities, and the Fund has delegated those powers and disclaims beneficial ownership for Section 13(d) purposes. No transactions have been reported since the prior amendment; the reported percentage reflects an increase in the issuer’s outstanding shares.